Asciminib

BRAND NAMES

Scemblix – used for the treatment of chronic myeloid leukemia resistant to prior tyrosine kinase inhibitors.

MECHANISM OF ACTION 

Asciminib is an allosteric inhibitor of BCR-ABL1 used in chronic myeloid leukemia. It binds to the myristoyl pocket, restoring the kinase’s inactive conformation and blocking its signaling. Unlike traditional TKIs, it is non-ATP-competitive, allowing activity against many TKI-resistant BCR-ABL1 mutations.

PHARMACOKINETICS

Absorption 

Asciminib is administered orally and is absorbed through the gastrointestinal tract, with peak plasma concentrations usually reached within 3 to 4 hours after dosing. While food may slightly delay its absorption, it does not significantly affect the total bioavailability of the drug. Asciminib demonstrates moderate oral bioavailability, ensuring sufficient systemic exposure to effectively inhibit BCR-ABL1 in patients with chronic myeloid leukemia.

Distribution 

Asciminib is widely distributed in the body with a moderate volume of distribution. It is highly protein-bound, mainly to albumin, which helps maintain a stable active concentration and ensures effective delivery to target tissues.

Metabolism 

Asciminib is primarily metabolized in the liver, mainly by the CYP3A4 enzyme. It undergoes oxidative metabolism to form inactive metabolites, with minimal contribution from other pathways. This hepatic metabolism influences dosing considerations, especially when used with strong CYP3A4 inhibitors or inducers.

Elimination 

Asciminib is eliminated mainly through feces, with a smaller portion excreted in urine. Its elimination involves both unchanged drug and metabolites. The drug has a half-life of approximately 7–8 hours, allowing for twice-daily or once-daily dosing depending on the regimen.

PHARMACODYNAMICS 

Asciminib selectively inhibits the BCR-ABL1 kinase by binding to its myristoyl pocket, stabilizing the inactive conformation of the protein. This blocks downstream signaling pathways that drive leukemic cell proliferation and survival. Its non-ATP-competitive mechanism allows activity against many BCR-ABL1 mutations that confer resistance to conventional TKIs, leading to reduced leukemic burden and improved hematologic and molecular responses in chronic myeloid leukemia patients.

ADMINISTRATION 

Asciminib is administered orally in the form of tablets. The dosing schedule depends on the indication and patient response, typically given once or twice daily. 

DOSAGE AND STRENGTH 

Asciminib is available as 20 mg, 40 mg, and 80 mg oral tablets. The typical dose for chronic myeloid leukemia patients resistant to prior TKIs is 40 mg twice daily. In cases with the T315I mutation or other resistant forms, higher doses, such as 80 mg once or twice daily, may be used under medical supervision. Dose adjustments may be necessary for patients with liver or kidney impairment or when taken with medications that strongly affect CYP3A4 activity.

DRUG INTERACTIONS 

Asciminib is metabolized by CYP3A4, so inhibitors can increase its levels and inducers can reduce its effectiveness. Being highly protein-bound, it may interact with other protein-bound drugs. Dose adjustments or monitoring are recommended when used with such medications.

FOOD INTERACTIONS 

Asciminib can be taken with or without food, as food does not significantly affect its absorption or overall bioavailability. High-fat meals may slightly delay peak plasma levels, but this does not impact its therapeutic effect.

CONTRAINDICATIONS 

Asciminib is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with severe hepatic or renal impairment, and it should not be used with drugs that strongly interact via CYP3A4 without proper monitoring.

SIDE EFFECTS 

Common side effects of Asciminib include: 

• Fatigue

• Nausea

• Headache

• Diarrhea

• Musculoskeletal pain

TOXICITY 

Asciminib is generally well tolerated, but excessive exposure or prolonged use can lead to hematologic toxicity such as neutropenia, thrombocytopenia, and anemia. Hepatotoxicity may occur, reflected by elevated liver enzymes. Rarely, serious effects like pancreatitis, QT prolongation, or cardiovascular events have been reported. Regular monitoring of blood counts, liver function, and ECG is recommended to minimize toxicity risks.